60124-83-6

Usage

Uses

Used in Pharmaceutical Industry:
ANTHRANILIC-3,4,5,6-D4 ACID is used as an internal standard in the synthesis of labeled drugs of abuse. Its application is crucial for accurate quantification and identification of these substances in forensic and clinical settings. The stable isotope labeling ensures that the compound behaves similarly to the target drug during analysis, allowing for precise measurements and reducing the risk of false results.
Used in Biomedical Research:
ANTHRANILIC-3,4,5,6-D4 ACID is used in the quantitative profiling of tryptophan metabolites. Tryptophan is an essential amino acid that plays a vital role in various biological processes, including the synthesis of proteins, neurotransmitters, and other biomolecules. The deuterated form of anthranilic acid allows researchers to track and quantify tryptophan metabolites in biological samples, providing valuable insights into the metabolism and function of this important amino acid. This application is particularly relevant in the study of various diseases and conditions that involve altered tryptophan metabolism, such as cancer, neurological disorders, and immune system dysfunction.

Upstream product

• 118-92-3 anthranilic acid 
• 4165-61-1 aniline-d5 
• 54354-03-9 ethyl benzoate-d₅ 

Downstream Products

• 646502-89-8 2-fluorobenzoic acid-d₄ 

Relevant academic research and scientific papers

Incorporation of anthranilate-d4 into DIMBOA in maize

2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one (DIMBOA) is synthesized in maize from anthranilic acid-d4 with high retention of deuterium. Retention of deuterium is only consistent with a mechanism of oxidative decarboxylation of o-carboxyanilinoribulose-5-phosphate or other anthranilate derivative via an intermediate in which oxygenation occurs at the carboxyl-bearing ortho carbon before decarboxylation

Lyomesophases of the Diethylammonium Flufenamate-Water System Studied by Deuterium NMR Spectroscopy

It was confirmed by using 2H NMR spectroscopy that mixtures of water and diethylammonium flufenamate (DEAF) form lyomesophases in the concentration range 2.5-60 wtpercent DEAF.Depending on the concentration of the DEAF, two phases are formed with differen

DEUTERATED SGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine onophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8 and Y9 is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.